AstraZeneca's oral diabetes treatment gets European regulatory approval

07:23 25/03/2019
StockMarketWire.com - AstraZeneca said European regulators had approved its supplementary oral treatment for overweight type-one diabetic patients, whose glucose levels were not adequately controlled with insulin alone.

'The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy,' the company said.

This marked the first approval of Forxiga for the treatment of patients with T1D.

The approval was based on data from the Phase III DEPICT clinical programme for Forxiga in T1D.

Results from the trial had demonstrated significant and clinically-meaningful reductions from baseline in average blood glucose levels HbA1c, weight and total daily insulin dose at 24 and 52 weeks.





Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
13:27 Cyprus garners strong demand for debut...
source: FT.com
13:19 FirstFT: Today’s top stories 
source: FT.com
13:15 Lex letter from Seoul: Starbucks’...
source: FT.com
13:09 Disney heiress steps up campaign over...
source: FT.com
13:07 UK deficit hits 17-year low; Bank of...
source: The Guardian
13:04 Pivot to data and technology helps Nasdaq...
source: FT.com
12:58 Boeing revenues hit by more than $1bn by...
source: FT.com
12:58 Boeing results reveal powerful blow from...
source: FT.com
12:54 AT&T revenues miss as it loses TV and...
source: FT.com
12:51 Names in the frame to be Bank of England...
source: The Guardian
[more ...]